Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CStone Out-Licenses China CTLA-4 Rights to Hengrui in $200 Million Deal

publication date: Nov 22, 2021

Suzhou CStone Pharma out-licensed greater China rights for its CTLA-4 mAb to Jiangsu Hengrui Pharma in a $200 million agreement. Hengrui will have rights to develop, manufacture and commercialize CS1002 in the territories. CStone has completed a successful China Phase I trial of CS1002 in combination with its PD-1 that enrolled patients with melanoma, hepatocellular carcinoma and microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) tumors. The company will receive up to $200 million in upfront and milestone payments, plus double-digit royalties from Hengrui. More details....

Stock Symbols:  (HK: 2616) (SHA: 600276)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022